Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Shield Bio logo — Combating antibiotic resistance through innovative genomic t...

Shield Bio

Combating antibiotic resistance through innovative genomic testing to ensure treatable infections remain manageable and prevent a future health crisis.

Founded 2016 Izmir Pre Seed Total: $12.10M Biotechnology, Health Care

General Information

Company Name Shield Bio
Founded Year 2016
Location Izmir
Industries Biotechnology, Health Care
Funding Stage Pre Seed
Social

Get notified when Shield Bio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Shield Bio

Shield Bio is a biotechnology startup dedicated to fighting antibiotic resistance through innovative genomic testing. The company's slogan captures its mission succinctly, emphasizing the importance of managing treatable infections to stave off a potential health crisis. With a founding year of 2016, Shield Bio operates in the biotechnology and healthcare industries, addressing a pressing global healthcare issue. The alarming prediction that antibiotic-resistant pathogens could surpass cancer in mortality rates by 2050 underscores the urgency of Shield Bio's work. The company highlights the escalating challenges posed by antibiotic resistance, pointing out the shift from simple oral antibiotics to increasingly complex and painful treatments for once manageable infections. Shield Bio emphasizes the severe health implications for patients as a result of these developments, stressing the gravity of the situation. One example cited by Shield Bio is the concerning case of gonorrhea, which has developed resistance to over ten different antibiotics, leaving only one effective treatment, which is also showing signs of resistance. The rapidly spreading antibiotic resistance, with 820,000 new infections annually in the U.S., has prompted the CDC to classify resistant gonorrhea as an urgent threat, their highest alert level. Shield Bio's solution lies in its innovative genomic testing platform, which enables STI clinics to identify antibiotic-resistant strains of gonorrhea and other pathogens in their patients. This, in turn, allows for the selection of effective antibiotics, thus curbing the spread of antibiotic resistance. The startup's focus on providing practical, immediate solutions to a critical healthcare issue demonstrates its potential to make a significant impact on public health. The company's most recent milestone was the Pre Seed Round investment on 01 April 2019, signifying a vote of confidence from investors in Shield Bio's mission and technological approach. While the specific investor details are not available, this investment underscores the recognition of Shield Bio's potential to address a pressing global health issue. As Shield Bio continues to develop and deploy its innovative genomic testing platform, it stands poised to contribute meaningfully to the fight against antibiotic resistance and the preservation of effective treatments for infectious diseases.

Taxonomy: Genomic Testing, Antibiotic Resistance, STI Clinics, Pathogen Identification, Health Crisis Prevention, Innovative Medical Solutions

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Pre Seed Round •••••• - 01 Apr 2019
Series A •••••• 10
Investor Investor Investor Investor Investor Investor
•••• •••• 		23 May 2018
Seed Round •••••• - 23 Feb 2017

Shield Bio Alternatives & Competitors

Shield Bio vs
Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals United States

Fighting against antimicrobial resistance is at the core of our technology and our people.

Grant
14 employees
Biopharma, Biotechnology
Shield Bio vs
Validus Cellular Therapeutics
Validus Cellular Therapeutics United States

Treating Untreatable Infections

Debt Financing
3 employees
Health Care, Health and Wellness
Shield Bio vs
First Light Diagnostics
First Light Diagnostics United States

First Light Diagnostics develops innovative diagnostic tests that enable rapid and accurate detectio...

Grant
27 employees
Biotechnology, Health Care

FAQ About Shield Bio

Combating antibiotic resistance through innovative genomic testing to ensure treatable infections remain manageable and prevent a future health crisis.
Shield Bio was founded in 2016.
Shield Bio is headquartered in Izmir.
Shield Bio operates in the following industries: Biotechnology, Health Care.
Shield Bio has completed 3 funding rounds, raising a total of $12.10M. The latest funding stage is Pre Seed.
Top alternatives and competitors to Shield Bio include Tetraphase Pharmaceuticals, Validus Cellular Therapeutics, First Light Diagnostics, Nuclease Probe Technologies, Inc., Madam Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Shield Bio and Tetraphase Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Shield Bio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes